AR076645A1 - Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales. - Google Patents
Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales.Info
- Publication number
- AR076645A1 AR076645A1 ARP100101286A ARP100101286A AR076645A1 AR 076645 A1 AR076645 A1 AR 076645A1 AR P100101286 A ARP100101286 A AR P100101286A AR P100101286 A ARP100101286 A AR P100101286A AR 076645 A1 AR076645 A1 AR 076645A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- saturated
- group
- compounds
- synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente solicitud se refiere a derivados de resorcinol sustituidos, que inhiben la actividad de la proteína de choque térmico HSP90. Por lo tanto, los compuestos de la solicitud son utiles para tratar enfermedades proliferativas tal como el cáncer y enfermedades neurodegenerativas. La presente solicitud también proporciona procesos para preparar estos compuestos, composiciones farmacéuticas que los comprenden, métodos para tratar enfermedades y las composiciones farmacéuticas que comprenden estos compuestos. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) donde Z es -CH=CH-, -(CH2)p, donde p es 0, 1, 2 o 3, NH, O, S, >S=O, >SO2 o >C=O; R es un grupo opcionalmente sustituido alquilo C1-7 lineal o ramificado, alquenilo C2-7 o alquinilo C2-7, cicloalquilo C3-7, cicloalquenilo C4-7, fenilo, naftilo, heteroarilo de 5 o 6 miembros, anillo heterocíclico saturado o parcialmente saturado que comprende uno o más átomos de oxígeno, azufre o nitrogeno, o es un grupo CONHR2, CH2NHR2, NHCOR2 o NHCONHR2 donde R2 es un grupo opcionalmente sustituido alquilo C1-7 lineal o ramificado, alquenilo C2-7 o alquinilo C2-7, cicloalquilo C3-7, cicloalquenilo C4-7, fenilo, naftilo, heteroarilo de 5 o 6 miembros, anillo heterocíclico saturado o parcialmente saturado que comprende uno o más átomos de oxígeno, azufre o nitrogeno; X es CH, N, NH u O; W e Y son independientemente CH, N, NH, O o S; R1 es un grupo NH2, NHCONHR2, NHCOR2, NHSO2R2 o CONHR2, donde R2 es como se definio más arriba; donde el anillo que contiene X, Y y W definidos más arriba es un grupo heteroarilo, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09158367 | 2009-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076645A1 true AR076645A1 (es) | 2011-06-29 |
Family
ID=42270238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101286A AR076645A1 (es) | 2009-04-21 | 2010-04-19 | Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8993556B2 (es) |
| EP (1) | EP2421833B1 (es) |
| JP (1) | JP5731479B2 (es) |
| CN (1) | CN102438988B (es) |
| AR (1) | AR076645A1 (es) |
| ES (1) | ES2533954T3 (es) |
| HK (1) | HK1166077A1 (es) |
| TW (1) | TW201041856A (es) |
| WO (1) | WO2010121963A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011274369A1 (en) * | 2010-07-02 | 2012-12-06 | Ventana Medical Systems, Inc. | Hapten conjugates for target detection |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF |
| EP3013341A4 (en) * | 2013-06-26 | 2017-02-08 | Proteostasis Therapeutics, Inc. | Methods of modulating cftr activity |
| EP3194975A4 (en) | 2014-09-17 | 2018-05-02 | Memorial Sloan Kettering Cancer Center | Hsp90-targeted inflammation and infection imaging and therapy |
| WO2016054560A1 (en) | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| CN109422690A (zh) * | 2017-08-31 | 2019-03-05 | 浙江省化工研究院有限公司 | 一种制备1-烷基-3-烷基吡唑-5-甲酸酯的方法 |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| CN109364045B (zh) * | 2018-10-21 | 2020-08-21 | 郑州大学第一附属医院 | 一种热休克蛋白90抑制剂及在肝癌治疗方面的应用 |
| JP7156154B2 (ja) * | 2019-04-18 | 2022-10-19 | 株式会社島津製作所 | 培地処理システム及び培地処理方法 |
| MD3986890T2 (ro) | 2019-06-18 | 2024-04-30 | Pfizer | Derivați de benzizoxazolsulfonamide |
| TWI771766B (zh) * | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| AU2021215396A1 (en) | 2020-02-03 | 2022-09-29 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| IL300090A (en) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Pharmaceutical preparations containing VENGLUSTAT |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2073284B1 (es) * | 1969-12-23 | 1973-07-13 | Ferlux | |
| DE2250343A1 (de) | 1972-10-13 | 1974-04-18 | Thiemann Chem Pharm Fab | 4,6-disubstituierte resorcinverbindungen |
| IL111613A0 (en) * | 1993-11-12 | 1995-01-24 | Rhone Poulenc Rorer Ltd | Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them |
| EP1218336A2 (en) | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| WO2003053368A2 (en) * | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | Chalcone derivatives and their use to treat diseases |
| JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| DK1611112T3 (da) | 2003-02-11 | 2012-11-19 | Cancer Res Inst | Isoxazolforbindelser som hæmmere af varmechokproteiner |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| US7538241B2 (en) | 2003-12-26 | 2009-05-26 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90 family protein inhibitors |
| JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
| JP2006306755A (ja) * | 2005-04-27 | 2006-11-09 | Nippon Kayaku Co Ltd | 新規なピラゾール誘導体とそれを有効成分とするｈｓｐ９０阻害剤 |
| DK2118077T3 (en) * | 2007-02-08 | 2015-03-09 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 ACTIVITY |
| GB0722680D0 (en) * | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
-
2010
- 2010-04-16 CN CN201080017562.7A patent/CN102438988B/zh active Active
- 2010-04-16 US US13/264,888 patent/US8993556B2/en active Active
- 2010-04-16 WO PCT/EP2010/055026 patent/WO2010121963A1/en active Application Filing
- 2010-04-16 JP JP2012506450A patent/JP5731479B2/ja active Active
- 2010-04-16 ES ES10714268.9T patent/ES2533954T3/es active Active
- 2010-04-16 EP EP10714268.9A patent/EP2421833B1/en active Active
- 2010-04-19 TW TW099112135A patent/TW201041856A/zh unknown
- 2010-04-19 AR ARP100101286A patent/AR076645A1/es unknown
-
2012
- 2012-07-11 HK HK12106799.6A patent/HK1166077A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2533954T3 (es) | 2015-04-16 |
| WO2010121963A1 (en) | 2010-10-28 |
| US8993556B2 (en) | 2015-03-31 |
| EP2421833B1 (en) | 2015-01-14 |
| JP5731479B2 (ja) | 2015-06-10 |
| JP2012524743A (ja) | 2012-10-18 |
| HK1166077A1 (en) | 2012-10-19 |
| EP2421833A1 (en) | 2012-02-29 |
| CN102438988A (zh) | 2012-05-02 |
| CN102438988B (zh) | 2015-06-24 |
| TW201041856A (en) | 2010-12-01 |
| US20120046266A1 (en) | 2012-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076645A1 (es) | Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales. | |
| AR107616A1 (es) | Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CL2011001967A1 (es) | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. | |
| CR20130534A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| PE20090060A1 (es) | ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| PE20201256A1 (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas | |
| AR082968A1 (es) | Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR091490A1 (es) | Antagonistas de iap | |
| CL2012000003A1 (es) | Compuestos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida sustituida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y uso de dichos compuestos como inhibidores de fosforilacion de akt (pkb) para el tratamiento del cancer. | |
| BR112013008675A2 (pt) | métodos e composições para o tratamento de diabetes e dislipidemia | |
| AR072880A1 (es) | Derivados nitrogenados de la pancratistatina | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| AR042910A1 (es) | Compuestos de pirazolopirimidina y procedimiento para preparar el mismo y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |